Elizabeth Vroom
Elizabeth Vroom has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Eugenio Mercuri
Pediatric Neurology Unit Fondazione Policlinico Universitario A. Gemelli IRCCS Rome Italy
2 shared publications A G Mayhew
John Walton Muscular Dystrophy Research Centre Institute of Genetic Medicine Newcastle upon Tyne UK
1 shared publication- Adrian Tassoni
Medical Center – University of Freiburg, University of Freiburg
1 shared publication - Anna Maria Gerdina Pasmooij
Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands; Dutch Medicines Evaluation Board, Utrecht, The Netherlands
1 shared publication - Annemieke Aartsma-Rus
Department of Human Genetics, Leiden University Medical Center, the Netherlands
1 shared publication - Antonio Atalaia
ERN EURO-NMD, University Hospitals Pitié Salpêtrière, Paris, France
1 shared publication
Latest Publications
- Open Access
- 4 October 2023
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 190 (2) , 268-270
Harmonization of outcomes in epidermolysis bullosa: report of the Core Outcome Sets for Epidermolysis Bullosa (COSEB) kick-off meeting
The COSEB kick-off meeting was organized in April 2023, and highlighted the stakeholder perspectives on the unmet and urgent need to work towards reasonable harmonization of outcome measurement in epidermolysis bullosa (EB) by developing core outcome sets for the different EB types. Standardized and uniform outcome assessment holds great promise to reduce selective reporting, improve the comparability and pooling of treatment outcomes, and enhance the efficacy of future research in EB.
- 4 October 2023
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 190 (2) , 268-270
Open AccessHarmonization of outcomes in epidermolysis bullosa: report of the Core Outcome Sets for Epidermolysis Bullosa (COSEB) kick-off meeting
The COSEB kick-off meeting was organized in April 2023, and highlighted the stakeholder perspectives on the unmet and urgent need to work towards reasonable harmonization of outcome measurement in epidermolysis bullosa (EB) by developing core outcome sets for the different EB types. Standardized and uniform outcome assessment holds great promise to reduce selective reporting, improve the comparability and pooling of treatment outcomes, and enhance the efficacy of future research in EB.
- 3 October 2023
- Published by Elsevier in Neuromuscular Disorders
- Vol. 33, S145
P203 Proven interoperability of five neuromuscular rare disease registries
- 3 October 2023
- Published by Elsevier in Neuromuscular Disorders
- Vol. 33, S145
P203 Proven interoperability of five neuromuscular rare disease registries
- 1 July 2018
- Published by Elsevier in Neuromuscular Disorders
- Vol. 28 (7) , 619-623
Meeting report of the “Regulatory Exchange Matters” session at the 5th International TREAT-NMD Conference:
- 1 July 2018
- Published by Elsevier in Neuromuscular Disorders
- Vol. 28 (7) , 619-623
Meeting report of the “Regulatory Exchange Matters” session at the 5th International TREAT-NMD Conference:
- Open Access
- 26 September 2016
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 59 (2) , 224-231
Development of a patient‐reported outcome measure for upper limb function in Duchenne muscular dystrophy: DMD Upper Limb PROM
Aim: To develop a patient‐reported outcome measure (PROM) assessing upper limb function related to activities of daily living (ADL) that cannot be observed in a clinical setting, specifically for patients with Duchenne muscular dystrophy (DMD) across a wide age range, applicable in the different stages of the disease.Method: The developmental process was based on US Food and Drug Administration guidelines. This included item generation from a systematic review of existing tools and expert opinion on task difficulty and relevance, involving individuals with DMD. Cultural aspects affecting ADL were taken into consideration to make this tool applicable to the broad DMD community. Items were selected in relation to a conceptual framework reflecting disease progression covering the full range of upper limb function across different ADL domains.Results: After pilot testing and iterative Rasch analyses, redundant or clinically irrelevant items were removed. The final questionnaire consists of 32 items covering four domains of ADL (food, self‐care, household and environment, leisure and communication). Test–retest reliability was excellent.Interpretation: A DMD‐specific upper limb PROM was developed on the basis of clinical relevance and psychometric robustness. Its main purpose is to document the patient self‐reported natural history of DMD and assess the efficacy of interventions.
- 26 September 2016
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 59 (2) , 224-231
Open AccessDevelopment of a patient‐reported outcome measure for upper limb function in Duchenne muscular dystrophy: DMD Upper Limb PROM
Aim: To develop a patient‐reported outcome measure (PROM) assessing upper limb function related to activities of daily living (ADL) that cannot be observed in a clinical setting, specifically for patients with Duchenne muscular dystrophy (DMD) across a wide age range, applicable in the different stages of the disease.Method: The developmental process was based on US Food and Drug Administration guidelines. This included item generation from a systematic review of existing tools and expert opinion on task difficulty and relevance, involving individuals with DMD. Cultural aspects affecting ADL were taken into consideration to make this tool applicable to the broad DMD community. Items were selected in relation to a conceptual framework reflecting disease progression covering the full range of upper limb function across different ADL domains.Results: After pilot testing and iterative Rasch analyses, redundant or clinically irrelevant items were removed. The final questionnaire consists of 32 items covering four domains of ADL (food, self‐care, household and environment, leisure and communication). Test–retest reliability was excellent.Interpretation: A DMD‐specific upper limb PROM was developed on the basis of clinical relevance and psychometric robustness. Its main purpose is to document the patient self‐reported natural history of DMD and assess the efficacy of interventions.